Research & Educational Use Only. This protocol guide is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before beginning any research protocol.
GW-501516 (Cardarine) is a selective PPARdelta receptor agonist developed by GlaxoSmithKline. It dramatically enhances endurance, fat oxidation, and lipid metabolism. Development was abandoned after animal studies showed cancer at extreme doses. It is not a SARM.
Protocol Overview
Compound
GW-501516 (Cardarine / Endurobol)
Category
PPARdelta Receptor Agonist (Metabolic Modulator)
Mechanism
Activates PPARdelta, shifting cellular energy metabolism from glucose to fatty acid oxidation. Upregulates fat-burning genes, increases mitochondrial biogenesis, improves lipid profile (HDL up, LDL and triglycerides down), and dramatically enhances endurance capacity
Half-Life
16-24 hours
Form
Oral liquid or capsule
Route
Oral
Frequency
Once daily
Cycle Length
8-12 weeks
Dosing Protocol
Protocol
Dose
Frequency
Route
Duration
Standard
10 mg
1x daily
Oral
8 weeks
Enhanced
15 mg
1x daily
Oral
8-10 weeks
Maximum
20 mg
1x daily
Oral
8-12 weeks
Expected Timeline
Week 1-2
Enhanced endurance within days. Ability to sustain cardiovascular exercise significantly increased.
Week 3-4
Major endurance and fat loss effects. Lipid panel improves (HDL increase, triglycerides decrease).
Week 5-6
Peak fat loss effects. Body composition changes clearly visible. Endurance at maximum enhancement.
Week 7-8
Continued benefits. Lipid profile significantly improved. Good stopping point for standard cycle.
Week 9-12
Extended cycle for experienced users. No hormonal suppression to manage.
Side Effects & Monitoring
Common Side Effects
Generally very well tolerated at standard doses
Rare headaches
Occasional mild GI discomfort
Potential for increased appetite
Precautions
Cancer concerns: rodent studies showed tumor development at high doses over 2 years
No long-term human safety data
Does not suppress testosterone - no PCT needed
Banned by WADA for athletic competition
Individual risk assessment essential given cancer data
